New targeted combination therapies with higher efficacy and less side effects
Current therapies for majority of metastatic cancers are marginally effective at best. 5-year survival rates being 9% for lung cancer, 7% for gastric cancer, > 3% for pancreatic cancer, etc
Our Human Disease model enables identification of synergistic targets to achieve complete tumor elimination
Enable patients’ own immune system to fight cancer as well as enhance the efficacy of multiple Immunotherapeutic that have failed.
Many tumors evade the patient’s own immune system. In addition, multiple immuno-based therapies by exploiting “cold tumor microenvironment (TME)”
Our disease models can be designed to identify master switches that can transform the TME from cold to hot and enable efficacy of multiple Immunotherapies.
Model Profiling
As we advance our understanding of the Human Disease Models, we believe that Qureator’s platform can bring transformative approaches to treating a wide range of diseases.
At Qureator, we are committed to pushing the boundaries of human biology and use our complex disease models to identify novel molecular targets and targets combinations leading to identification of powerful therapies that can significantly improve patient outcomes.